Loading
companiesCompany
Kopra Bio
Kopra Bio engineers viruses that teach the immune system to kill cancer, starting with glioblastoma, the most aggressive brain cancer.
Overview
Kopra Bio, a UCSF spin-out, develops genetically engineered immunotherapeutic viruses designed to prime the immune system against tumours, with glioblastoma as the first indication. Its YC profile reports that in an aggressive mouse model of brain cancer the treatment raised survival from zero with the current approved therapy to 90 percent, a preclinical result that has not yet been tested in patients. The company is very small and preclinical; no sourced financing rounds are recorded.
Headquarters
San Francisco, CA, US
Funding
All startupsStartupYC S24
Investors
Type
Stage
Startup · Y Combinator Summer 2024
Website
Similar pages
- CompanyHumane Genomics
Shares Y Combinator, Oncolytic viruses and the tag yc.
- CompanyReverie Labs
Shares Y Combinator, Glioma & glioblastoma and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyMednet (theMednet)
Shares Y Combinator and the tag yc.
- CompanyAlixia
Shares Y Combinator and the tag yc.
- CompanyVelorum Therapeutics
Shares Y Combinator and the tag yc.
- CompanyDelee
Shares Y Combinator and the tag yc.
- CompanyResistanceBio (Viosera Therapeutics)
Shares Y Combinator and the tag yc.